Foghorn Therapeutics Stock News

Foghorn Therapeutics Inc. (NASDAQ:FHTX) with the stream of -4.68% also noticed, India Regions Financial Corporation (NYSE:RF) encountered a rapid change of 1.77% in the last hour of Tuesdays trading session. The post Todays Hot Mover: Foghorn Therapeutics Inc. (NASDAQ:FHTX), Regions Financial Corporation (NYSE:RF) appeared first on Stocks Equity .

Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) shares jumped 80.4% to close at $90.08 on Monday. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-cash transaction. Foghorn Therapeutics Inc. (NASDAQ: FHTX ) shares jumped 55% to close at $18.58. Loxo Oncology, an R&D group of Eli Lilly And Co (NYSE: LLY ), and Foghorn Therapeutics collaborated to create oncology medicines by applying Foghorn''s Gene Traffic Control platform. BELLUS Health Inc. (NASDAQ: BLU ) gained 48.2% to settle at $8.30 after the company announced topline data its Phase 2b SOOTHE trial of BLU-5937 in Refractory Chronic Cough. Petros Pharmaceuticals, Inc. (NASDAQ: PTPI ) surged 47.4% to close at $3.98 after gaining more than 14% on Friday. Energy Focus, Inc. (NASDAQ: EFOI ) gained 36.2% to close at $4.70. East Stone Acquisition Corporation (NASDAQ: ESSC ) jumped 31.4% to close at $18.40 after gaining over 8% on Friday. Puxin Limited (NYSE: NEW ) climbed 27.1% to settle at $0.41 after tumbling over 10% on Friday.

The clinical-stage biotech could reap as much as $1.3. billion from a new research and development pact with a heavy-hitting partner.

The clinical-stage biotech could reap as much as $1.3. billion from a new research and development pact with a heavy-hitting partner.

Shares of FHTX stock are surging today after the company announced a partnership with Eli Lilly. Here's what you should know.

Loxo Oncology , an R&D group of Eli Lilly And Co (NYSE: LLY ), and Foghorn Therapeutics Inc (NASDAQ: FHTX ) have collaborated to create oncology medicines by applying Foghorn''s Gene Traffic Control platform. The collaboration includes a co-development and co-commercialization agreement for Foghorn''s selective BRM oncology program and an additional undisclosed oncology target. In addition, the collaboration includes three additional discovery programs using Foghorn''s Gene Traffic Control platform. Under Full story available on Benzinga.com

(RTTNews) - The following are some of the stocks making big moves in Monday''s pre-market trading (as of 07.10 A.M. ET). In the Green Arena Pharmaceuticals, Inc. (ARNA) is up over 97% at $98.63 Foghorn Therapeutics Inc. (FHTX) is up over 35% at $16.27 Petros Pharmaceuticals, Inc. (PTPI) is up over 31% at $3.55 bluebird bio, Inc.

Jake Van Naarden, who rules the oncology roost at Eli Lilly, is back in the dealmaking game. Monday morning he uncorked a deal to provide Flagship-backed Foghorn Therapeutics $380 million $300 million in cash and $80 million for a premium equity deal to jump on board the biotechs

The stock price of Foghorn Therapeutics Inc. (NASDAQ: FHTX) increased by over 30% pre-market today. This is why it happened.

HC Wainwright assumed coverage on shares of Foghorn Therapeutics (NASDAQ:FHTX) in a report issued on Monday morning, Analyst Price Targets reports. The brokerage issued a buy rating and a $25.00 target price on the stock. Separately, Zacks Investment Research lowered Foghorn Therapeutics from a buy rating to a hold rating in a research note on []

Vanguard Group Inc. grew its position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) by 67.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 683,778 shares of the companys stock after purchasing an additional 276,444 shares during the quarter. Vanguard Group Inc. owned approximately 1.86% of []

CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression

FHD-609 is a first-in-class, highly potent and selective protein degrader of BRD9

CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically deter

CAMBRIDGE, Mass., July 09, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically deter